Cargando…
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose
Vaccination with typhoid conjugate vaccines (TCV) is a major part of typhoid prevention. However, little is known about long-term immune persistence following vaccination with TCVs. In this phase-2, randomized double-blind trial (NCT03527355), 285 children aged 6–23 months were randomized to one of...
Autores principales: | Capeding, Maria Rosario, Tadesse, Birkneh Tilahun, Sil, Arijit, Alberto, Edison, Kim, Deok Ryun, Park, Eun Lyeong, Park, Ju Yeon, Yang, Jae Seung, Eluru, Jagadeesh Reddy, Jo, Sue-Kyoung, Kim, Hun, Yang, Seon-Young, Ryu, Ji Hwa, Park, Hokeun, Shin, Jong Hoon, Lee, Yoonyeong, Kim, Jerome H., Mojares, Zenaida Reynoso, Wartel, T. Anh, Sahastrabuddhe, Sushant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795159/ https://www.ncbi.nlm.nih.gov/pubmed/35087084 http://dx.doi.org/10.1038/s41541-022-00434-8 |
Ejemplares similares
-
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age
por: Carlos, Josefina Cadorna, et al.
Publicado: (2022) -
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study
por: Capeding, Maria Rosario, et al.
Publicado: (2020) -
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial
por: Kumar Rai, Ganesh, et al.
Publicado: (2022) -
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report
por: Capeding, Maria Rosario, et al.
Publicado: (2020) -
Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT)
por: Lee, Eun Young, et al.
Publicado: (2020)